Published in Cancer Weekly, December 10th, 2002
The University of Texas M.D. Anderson Cancer Center investigators have studied the effects of PKI166 on HRCCs in vitro and in orthotopic transplantations in nude mice. They have also examined whether or not gemcitabine augments the effects of PKI166.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.